KRAS late­com­er Roche draws cau­tious com­par­isons to Am­gen, Mi­rati in ear­ly da­ta

On a quest not just to catch up with, but leapfrog, Am­gen and Mi­rati in the KRAS race, Roche has re­leased ear­ly monother­a­py da­ta on its in-house can­di­date across a va­ri­ety of can­cers.

Roche, which pre­sent­ed some di­vara­sib da­ta at the AACR con­fer­ence in April, spelled out the most com­pre­hen­sive set of re­sults to date around the KRAS G12C in­hibitor de­vel­oped by Genen­tech in the New Eng­land Jour­nal of Med­i­cine. The Phase I study, pub­lished late Wednes­day, fea­tured a to­tal of 137 pa­tients with non-small cell lung can­cer, col­orec­tal can­cer and oth­er sol­id tu­mors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER